Clinical Trial Update: Validation of an Alzheimer's Disease Marker by Fecal Assay of Amyloid Peptides and Tau Proteins

View source ↗

Summary

A clinical trial validating a fecal assay measuring amyloid peptides and tau proteins as a biomarker for Alzheimer's disease; currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Alzheimer Disease

Snippet

Sponsor: University Hospital, Grenoble | Conditions: Alzheimer Disease | Status: RECRUITING